BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its target price dropped by research analysts at Royal Bank Of Canada from $62.00 to $60.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada‘s price objective suggests a potential upside of 9.00% from the stock’s current price.
Several other equities research analysts have also recently weighed in on the company. Jefferies Financial Group boosted their price objective on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a “buy” rating in a research note on Monday, August 31st. Citigroup raised their price objective on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Raymond James Financial upgraded BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 target price for the company in a report on Monday, October 12th. HC Wainwright restated a “neutral” rating and set a $60.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, September 10th. Finally, Barclays raised their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $88.09.
Read Our Latest Stock Report on BioMarin Pharmaceutical
BioMarin Pharmaceutical Price Performance
Shares of NASDAQ:BMRN traded down $2.39 on Tuesday, reaching $55.05. The company’s stock had a trading volume of 411,376 shares, compared to its average volume of 2,103,768. The company has a 50-day simple moving average of $60.43 and a 200 day simple moving average of $58.46. BioMarin Pharmaceutical has a 52-week low of $49.26 and a 52-week high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The company has a market cap of $10.66 billion, a P/E ratio of 149.34, a PEG ratio of 0.61 and a beta of 0.22.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last announced its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.31. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the prior year, the company earned $0.12 EPS. The business’s revenue was up 32.0% compared to the same quarter last year. As a group, equities research analysts anticipate that BioMarin Pharmaceutical will post 2.59 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Kestra Advisory Services LLC boosted its holdings in BioMarin Pharmaceutical by 23.4% during the 3rd quarter. Kestra Advisory Services LLC now owns 4,520 shares of the biotechnology company’s stock valued at $271,000 after acquiring an additional 857 shares during the period. Bfsg LLC bought a new position in BioMarin Pharmaceutical in the 3rd quarter valued at $1,052,000. Oregon Public Employees Retirement Fund grew its position in BioMarin Pharmaceutical by 0.5% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company’s stock valued at $2,407,000 after acquiring an additional 200 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in BioMarin Pharmaceutical in the third quarter worth $186,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in BioMarin Pharmaceutical in the third quarter worth $705,000. Institutional investors own 98.71% of the company’s stock.
Key Stories Impacting BioMarin Pharmaceutical
Here are the key news stories impacting BioMarin Pharmaceutical this week:
- Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and broadly in line with estimates. Growth was led by a 44% increase in metabolic-condition revenue and a 12% increase in skeletal-condition revenue. Adjusted EPS of $0.23 substantially exceeded the consensus estimate for a loss of approximately $0.08. BioMarin Reports Third Quarter 2026 Financial and Operating Results
- Positive Sentiment: The company expanded its pipeline with a new investigational Fabry-disease asset and reported a May 30, 2027, FDA action date for VOXZOGO in hypochondroplasia. These developments support BioMarin’s longer-term growth prospects. BioMarin Reports Third Quarter 2026 Financial and Operating Results
- Positive Sentiment: Citi reiterated a Buy rating, arguing that the timing-related setback does not undermine BioMarin’s long-term potential and citing approximately 32% upside. Other commentary described the stock as potentially undervalued following the Fabry deal and mixed guidance. BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential
- Negative Sentiment: BioMarin lowered fiscal 2026 EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and set revenue guidance at $3.8–$3.9 billion versus a $3.9 billion consensus. The lower outlook may outweigh the quarterly earnings beat in the near term. BMRN Q3 Deep Dive
- Neutral Sentiment: Management characterized the outlook issue as primarily related to order timing, while acquired IPR&D charges also affected earnings expectations. Investors will likely focus on whether demand timing normalizes and whether the expanded pipeline generates future growth.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.
BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.
Recommended Stories
- Five stocks we like better than BioMarin Pharmaceutical
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
- Check Point’s Turnaround Could Be Closer Than Investors Think
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
